Central Retinal Vein Occlusion

Overview of diagnosis and treatment of central retinal vein occlusion.

What is a Central Retinal Vein Occlusion?

The inner layers of the retina receive their blood supply from the central retinal artery. The blood returns to the heart through the central retinal vein. Both vessels enter the eye through a small opening in the middle of the optic nerve. Either because this opening shrinks or because the artery hardens or because of circulations problems, the central retinal vein can become partially or completely occluded. When a patient develops a central retinal vein occlusion (CRVO), they lose some or most of their central vision. The photograph of the retina on the right is of an eye with 20/50 visual acuity with a central retinal vein occlusion for 6 weeks. The retinal veins dilate and there are retinal hemorrhages. Patients often develop swelling of the central retina-cystoid macular edema--causing some of the vision loss. Without treatments, 25% of eyes improve, 50% stabilize, and 25% worsen.

Lucentis for Central Retinal Vein Occlusion

Monthly Lucentis therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 50 percent of patients have improved vision. Long term follow-up show that at 4 years, a little over half of the patients with central retinal vein occlusion require continued treatment to maintain the visual benefit.


Eylea for Central Retinal Vein Occlusion

Monthly Eylea therapy is also helpful in improving vision in patients with central retinal vein occlusion and macular edema. Without treatment about 15 percent of have visual improvement. With treatment about 60 percent of patients have improved vision.


Central Retinal Vein Occlusion NEWS

Below are current articles from a Google News Feed on Central Retinal Vein Occlusion

This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

MD Magazine

Disorganization of Retinal Inner Layers Linked to Visual Acuity Prognoses
MD Magazine
Patients with CRVO/HRVO who did not have DRIL at baseline reported greater gains in visual acuity after 6 months of AVF therapy. Meanwhile, patients in the CRVO/HRVO group who had increasing DRIL scores had lower improvement in visual acuity ...


Treat-and-extend regimen reduces injection burden in macular edema secondary to CRVO
Healio
A phase IV study to assess efficacy and safety of a treat-and-extend regimen of aflibercept for treatment of macular edema secondary to central retinal vein occlusion in naïve patients. NEUTON study. Presented at: Euretina; Sept. 20, 2018; Vienna ...


Business Wire (press release)

Altris.AI – The New Era of Retinal Diagnosis is Coming
Business Wire (press release)
Central Serous Retinopathy;. • Macular Pucker (Epiretinal Fibrosis);. • Degenerative Myopia;. • Vitreo-Macular Traction Syndrome;. • Vitreous Detachment;. • Macular Hole;. • Lamellar Macular Hole;. • Pseudohole;. • Central Retinal Vein Occlusion ...

and more »

Fairfield Current

Regeneron Pharmaceuticals Inc (REGN) Stake Lowered by Tiaa Fsb
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Regeneron Pharmaceuticals Inc (REGN) Holdings Cut by Schroder ...BharataPress
United Services Automobile Association Buys 18,886 Shares of ...XNewsPress
SEC FORM 4 - SEC.govSEC.gov

all 52 news articles »

MedicalResearch.com (blog)

Association of Disorganization of Retinal Inner Layers With Visual Acuity Response to Anti-VGEF Therapy for Macular ...
MedicalResearch.com (blog)
Seventy-five eyes had central retinal vein occlusion (CRVO) or hemi-retinal vein occlusion (HRVO), and 72 eyes had branch retinal vein occlusion (BRVO). Among the 147 patients, the mean patient age was 68.9 years, 75 (51 percent) were female and 72 (49 ...


RVC (Retinal Vein Occlusion) Market 2018 Superior Growth at a CAGR of 11.2% till 2023 | Diagnosis, Optical ...
MENAFN.COM
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...

and more »

Global Retinal Vein Occlusions market – industry analysis, share, growth, trends and forecast from 2018-2025
Trade Market Research
Retinal vein is divided into two different types such as; central retinal vein occlusion (CRVO) and branch retinal vein occlusion(BRVO). Central retinal vein occlusion when the main vein of the eye (Located at the optical nerve) becomes blocked. Branch ...


FDA Headlines

Why Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Duplixant Data Came at Just the Right Time
FDA Headlines
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

$5.22 EPS Expected for Regeneron Pharmaceuticals Inc (REGN) This Quarter
BharataPress
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.


Allergan to Showcase Continued Eye Care Innovation with New Data on Investigational Medicines at the American ...
PR Newswire (press release)
... treatments for the most prevalent eye conditions including glaucoma, ocular surface disease, and retinal diseases such as diabetic macular edema and retinal vein occlusion. Our eye care pipeline includes 13 additional agents for multiple ocular ...

and more »

FDA Headlines

Is it Time to Get Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on the Radar Again?
FDA Headlines
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Two-year data confirm efficacy of EYLEA® (aflibercept solution for injection) Treat and Extend dosing regimens for ...
PharmiWeb.com (press release)
... visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO) and visual impairment due to macular oedema secondary to branch retinal vein occlusion (BRVO); visual impairment due to diabetic macular oedema (DMO) and ...


Public Employees Retirement System of Ohio Purchases 223 Shares of Regeneron Pharmaceuticals Inc (REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Fairfield Current

Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Hold Rating from JPMorgan Chase & Co.
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 46 news articles »

Regeneron Pharmaceuticals (REGN) Price Target Increased to $410.00 by Analysts at Canaccord Genuity
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Odey Asset Management Group Ltd Has $2.83 Million Stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

XNewsPress

Flagship Harbor Advisors LLC Invests $159000 in Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
SEC FORM 4 - SEC.govSEC.gov

all 95 news articles »

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Stake Lowered by Dai Ichi Life Insurance Company Ltd
Fairfield Current
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

Marea Informative (blog)

Essex Investment Management Co. LLC Has $5.10 Million Position in Regeneron Pharmaceuticals Inc (REGN)
Marea Informative (blog)
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

PressOracle

Brokerages Anticipate Regeneron Pharmaceuticals Inc (REGN) Will Post Earnings of $5.22 Per Share
PressOracle
... neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

and more »

LANews By Abhishek Budholiya (press release) (blog)

Ongoing Industry Analysis Report Tracks the Forecasted Expansion of Cystoid Macular Edema Market for 2017 – 2025 ...
LANews By Abhishek Budholiya (press release) (blog)
Cystoid macular edema (CME) also known as Irvine Gass Syndrome is a painless disorder affecting the central retina or macula. This condition is characterized by multiple cysts like areas of fluid in ... Various risk factors associated with cystoids ...


Anti-VEGF treatment of macular edema associated with retinal vein occlusion: patterns of use and effectiveness in ...
Dove Medical Press
... months after the first injection included Snellen best-corrected visual acuity (BCVA), central retinal thickness (CRT) by time-domain optical coherence tomography (TD-OCT) or spectral-domain optical coherence tomography (SD-OCT), anti-VEGF ...

and more »

WPLG Local 10

Vasular condition leads to sudden sight loss
WPLG Local 10
Burgess was diagnosed with central retinal vein occlusion, or CRVO, a condition that causes a clot to form in the eye, leading to damaging pressure. "It was like someone threw a tomato at my eye," Burgess said. Cardiologist Dr. Adam Splaver said CRVO ...


IOP spikes more likely after treatment in certain patients
Healio
Patients with uveitis had the greatest mean IOP spike (24.3 mm Hg) compared with patients with central retinal vein occlusion (21.8 mm Hg), branch retinal vein occlusion (21.1 mm Hg) and (20.7 mm Hg) after a single injection. – by Robert Linnehan.


Bel Marra Health

Risk factors and causes of central retinal vein occlusion (CRVO)
Bel Marra Health
Poorly controlled high blood pressure may predispose you to the development and also the occurrence of central retinal vein occlusion. It has been found that up to 73 percent of patients over 50 years of age, as well as 25 percent of younger patients ...


Medgadget (blog)

Retinal Vein Occlusion Market Rising Demand Seen in Healthcare at a CAGR of 11.2% by 2023 | By Types Branch ...
Medgadget (blog)
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...


The Siver Times

Ukraine has banned the popular drug
The Siver Times
with macular edema, which was caused due to occlusion of the Central retinal vein or occlusion branch retinal vein;with inflammation of the posterior segment of the eye in the form of non-infectious uveitis;violation of vision due to diabetic macular ...

and more »

Retinal Vein Occlusion Market move up at a CAGR of 11.2% by Topmost Players | By Types Branch Retinal Artery ...
MENAFN.COM
The global retinal vein occlusion market is segmented on the basis of type, condition, diagnosis, treatment, and end user. On the basis of the type, it is segmented into branch retinal artery occlusion and central retinal vein occlusion. On the basis ...

and more »

Medgadget (blog)

Retinal Vein Occlusion Market Size and Trend by Branch and Central Retinal Vein Occlusion Type, Etc. Types and ...
Medgadget (blog)
Glaucoma is a condition where the eye pressure causes damage to the optic nerve. The increasing number of patients with glaucoma is leading the retinal vein occlusion market offering a huge growth opportunity to the market players. Moreover, the ...

and more »

Ozurdex® (dexamethasone 0.7mg) now available for millions of patients in China with macular edema secondary to ...
Markets Insider
Ozurdex® is the first approved intravitreal injection for RVO in China and is licensed for the treatment of macular edema following BRVO and CRVO. Allergan has accelerated access to this treatment in 27 hospitals across China, making it available as a ...

» Load more